Liquid biopsy feasibly predicted outcomes among patients with metastatic triple-negative breast cancer, study data showed.

“Traditionally, we would need to obtain a tissue biopsy to perform the whole-genome sequencing tests that could reveal potential DNA-level mutations driving a patient’s specific cancer. For metastatic breast cancer patients, however, tissue biopsy can be risky or painful,” Daniel Stover, MD, assistant professor of medicine at The Ohio State University Comprehensive Cancer Center, said in a press release. “Being able to do this type of genomic analysis from a simple blood draw allows us to get a picture of a patient’s specific cancer genomic characteristics in a less invasive way.”